Cartesian Therapeutics/$RNAC
1D1W1MYTD1Y5YMAX
About Cartesian Therapeutics
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
- Ticker
- $RNAC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 75
- Headquarters
- Frederick, United States
RNAC Metrics
BasicAdvanced
$278M
-
-$5.61
-
-
Price and volume
Market cap
$278M
52-week high
$11.80
52-week low
$5.60
Average daily volume
126K
Financial strength
Current ratio
7.475
Quick ratio
7.192
Long term debt to equity
-47.639
Total debt to equity
-50.99
Interest coverage (TTM)
-115.80%
Profitability
EBITDA (TTM)
-96.051
Gross margin (TTM)
-4,529.99%
Net profit margin (TTM)
-10,283.75%
Operating margin (TTM)
-6,679.69%
Effective tax rate (TTM)
5.71%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-17.43%
Return on equity (TTM)
237.79%
Valuation
Price to revenue (TTM)
168.274
Price to book
-2.2
Price to tangible book (TTM)
-1.03
Price to free cash flow (TTM)
-3.162
Free cash flow yield (TTM)
-31.63%
Free cash flow per share (TTM)
-2.904
Growth
Revenue change (TTM)
43.96%
Earnings per share change (TTM)
282.47%
What the Analysts think about RNAC
Analyst ratings (Buy, Hold, Sell) for Cartesian Therapeutics stock.
RNAC Financial Performance
Revenues and expenses
RNAC Earnings Performance
Company profitability
RNAC News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.